



HAL
open science

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95

Audrey Simon, Peoc'H Michel, Philippe Casassus, Eric Deconinck, P Colombat, Bernard Desablens, Olivier Tournilhac, Houchingue Eghbali, Ch Foussard, Jerome Jaubert, et al.

► **To cite this version:**

Audrey Simon, Peoc'H Michel, Philippe Casassus, Eric Deconinck, P Colombat, et al.. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. *British Journal of Haematology*, 2010, 151 (2), pp.159. 10.1111/j.1365-2141.2010.08329.x . hal-00569409

HAL Id: hal-00569409

<https://hal.science/hal-00569409>

Submitted on 25 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.




Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95

Journal:	<i>British Journal of Haematology</i>
Manuscript ID:	BJH-2010-00492.R1
Manuscript Type:	Ordinary Papers
Date Submitted by the Author:	02-Jun-2010
Complete List of Authors:	Simon, Audrey; CHU de grenoble, Hematology michel, peoc'h; hospital, anatomie pathologique Casassus, Philippe; Hôpital Avicenne, Department of Hematology DECONINCK, Eric; CHU Jean Minjot, Haematology COLOMBAT, P; University Hospital of Tours, Haematology Desablens, Bernard; CHU Amiens, Hematology Tournilhac, Olivier; CHU Hotel-Dieu, Clinical Haematology Eghbali, Houchingue; Institut Bergonié Bordeaux, Hematologie FOUSSARD, CH; University Hospital of Angers, Haematology Jaubert, Jerome; CHU Saint Etienne, Hematology Vilque, Jean-Pierre; CHU Reims, Department of Hematology Rossi, Jean François; CHU Montpellier, Haematology LUCAS, Virginie; Regional Hospital of Orleans, Oncology DELWAIL, V; CHU Poitiers, Haematology Thyss, Antoine; CHU Nice, Haematology Moloisel, Frederic; CHU Strasbourg, Haematology MILPIED, Noel; Universitu Hospital of Bordeaux, Haematology Le Gouill, steven; CHU Nantes, Service d'Hématologie clinique Lamy, Thierry; CHU Rennes, Haematology GRESSIN, R; CHU Grenoble, Hematology
Key Words:	T-CELL LYMPHOMA, CLINICAL TRIALS, CHOP
<p>Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.</p>	
<p>PTCL CHOP vs VIPrABVD revision BJH.docm</p>	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For Peer Review



Reduction in EFS Increase in EFS

review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60